scispace - formally typeset
Search or ask a question
Author

Anargyros Kapetanakis

Bio: Anargyros Kapetanakis is an academic researcher. The author has contributed to research in topics: Case fatality rate & Intensive care unit. The author has an hindex of 1, co-authored 1 publications receiving 2 citations.

Papers
More filters
Journal ArticleDOI
Thomas Chatzikonstantinou, Anargyros Kapetanakis, Lydia Scarfò1, Georgios Karakatsoulis2, David Allsup3, Alejandro Alonso Cabrero, Martin Andres4, Darko Antic5, Mónica Baile, Panagiotis Baliakas6, Panagiotis Baliakas7, Dominique Bron, Antonella Capasso1, Sofia Chatzileontiadou, Raul Cordoba, Juan-Gonzalo Correa, Carolina Cuéllar-García, Lorenzo De Paoli8, Maria Rosaria De Paolis, Giovanni Del Poeta9, Christos Demosthenous, Maria Dimou10, David Donaldson11, Michael Doubek12, Maria Efstathopoulou13, Barbara Eichhorst14, Shaimaa El-Ashwah15, Alicia Enrico, Blanca Espinet, Lucia Farina16, Angela Ferrari, Myriam Foglietta, Henrik Frederiksen17, Moritz Fürstenau14, José A. García-Marco, Rocío García-Serra, Massimo Gentile, Eva Gimeno, Andreas Glenthøj18, Maria Gomes da Silva, Odit Gutwein19, Yervand K Hakobyan, Yair Herishanu20, Jose Angel Hernandez-Rivas, Tobias Herold21, Idanna Innocenti22, Gilad Itchaki23, Ozren Jakšić, Ann Janssens24, Оlga B Kalashnikova, Elżbieta Kalicińska25, Linda Katharina Karlsson18, Arnon P. Kater26, Sabina Kersting, Jorge Labrador, Deepesh Lad27, Luca Laurenti22, Luca Laurenti28, Mark-David Levin29, Enrico Lista, Alberto Lopez-Garcia, Lara Malerba, Roberto Marasca30, Monia Marchetti, Juan Marquet, Mattias Mattsson6, Mattias Mattsson7, Francesca Romana Mauro31, Ivana Milosevic32, Fatima Miras, Marta Morawska33, Marta Morawska34, Marina Motta, Talha Munir, Roberta Murru, Carsten Utoft Niemann18, Raquel Nunes Rodrigues, Jacopo Olivieri, Lorella Orsucci, Maria Papaioannou, Miguel Arturo Pavlovsky, Inga Piskunova, Viola Maria Popov, Francesca Maria Quaglia35, Giulia Quaresmini, Kristian Qvist, Gianluigi Reda, Gian Matteo Rigolin36, Rosa Ruchlemer37, Gevorg Saghumyan, Amit Shrestha, Martin Simkovic38, Martin Spacek39, Paolo Sportoletti40, Oana Stanca41, Niki Stavroyianni, Tamar Tadmor, Doreen te Raa, Sanne H. Tonino26, Livio Trentin42, Ellen van der Spek, Michel van Gelder43, Roel van Kampen, Marzia Varettoni, Andrea Visentin42, Candida Vitale44, Ewa Wasik-Szczepanek, Tomasz Wróbel25, Lucrecia Yáñez San Segundo, Mohamed A. Yassin45, Marta Coscia44, Alessandro Rambaldi16, Emili Montserrat, Robin Foà31, Antonio Cuneo36, Kostas Stamatopoulos, Paolo Ghia1 
01 Nov 2021-Leukemia
TL;DR: In this paper, the authors investigated the impact of CLL-directed treatments on the course of Coronavirus disease 2019 (COVID-19) and found that patients with chronic lymphocytic leukemia (CLL) may be more susceptible to the disease due to age, disease, and treatment-related immunosuppression.
Abstract: Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41-0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02-1.04; HR = 1.79, 95% CI:1.04-3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.

46 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: In this article , the authors reported a continued growth in CAR-T cellular therapies to 1874 (+65%) patients in 2020 and the use of haploidentical donors increased while use of unrelated and sibling donors decreased.
Abstract: In 2020, 45,364 HCT in 41,016 patients, 18,796 (41%) allogeneic and 26,568 (59%) autologous in 690 centers were reported. Changes observed were as follows: total number of HCT -6.5%, allogeneic HCT -5.1%, autologous HCT -7.5%, and were more pronounced in non-malignant disorders for allogeneic HCT and in autoimmune disease for autologous HCT. Main indications were myeloid malignancies 10,441 (25%), lymphoid malignancies 26,120 (64%) and non-malignant disorders 2532 (6%). A continued growth in CAR-T cellular therapies to 1874 (+65%) patients in 2020 was observed. In allogeneic HCT, the use of haploidentical donors increased while use of unrelated and sibling donors decreased. Cord blood HCT increased by 11.7% for the first time since 2012. There was a significant increase in the use of non-myeloablative but a drop in myeloablative conditioning and in use of marrow as stem cell source. We interpreted these changes as being due to the SARS-CoV-2 pandemic starting early in 2020 in Europe and provided additional data reflecting the varying impact of the pandemic across selected countries and larger cities. The transplant community confronted with the pandemic challenge, continued in providing patients access to treatment. This annual report of the EBMT reflects current activities useful for health care planning.

37 citations

Journal ArticleDOI
19 May 2022-Blood
TL;DR: Patients with CLL with close hospital contactss and in particular those above 70 years of age with one or more comorbidities should be considered for closer monitoring and pre-emptive antiviral therapy upon a positive SARS-CoV-2 test.

32 citations

Journal ArticleDOI
TL;DR: Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021, but results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.
Abstract: Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p<0.001, HR 1.036), active malignancy (p<0.001, HR 2.215), severe COVID-19 (p=0.017, HR 2.270) and admission to ICU (p<0.001, HR 5.751) were risk factors for mortality at last day of follow up. There was no difference in OS rates in NHL vs CLL patients (p=0.306), nor in patients treated with or without BKIs (p=0.151). Mortality in ICU was 66% (CLL 61%, NHL 76%). Overall mortality rate decreased according to vaccination status, being 39% in unvaccinated patients, 32% and 26% in those having received one or two doses, respectively, and 20% in patients with a booster dose (p=0.245). Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021. These results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.

16 citations

Journal ArticleDOI
TL;DR: In this paper, the authors highlight several characteristics of γδ T cells and their interactions in leukemia and explore strategies for maximizing their antitumor functions, aiming to illustrate the findings destined for a better mobilization of these lymphocytes against the tumor.
Abstract: Recently, many discoveries have elucidated the cellular and molecular diversity in the leukemic microenvironment and improved our knowledge regarding their complex nature. This has allowed the development of new therapeutic strategies against leukemia. Advances in biotechnology and the current understanding of T cell-engineering have led to new approaches in this fight, thus improving cell-mediated immune response against cancer. However, most of the investigations focus only on conventional cytotoxic cells, while ignoring the potential of unconventional T cells that until now have been little studied. γδ T cells are a unique lymphocyte subpopulation that has an extensive repertoire of tumor sensing and may have new immunotherapeutic applications in a wide range of tumors. The ability to respond regardless of human leukocyte antigen (HLA) expression, the secretion of antitumor mediators and high functional plasticity are hallmarks of γδ T cells, and are ones that make them a promising alternative in the field of cell therapy. Despite this situation, in particular cases, the leukemic microenvironment can adopt strategies to circumvent the antitumor response of these lymphocytes, causing their exhaustion or polarization to a tumor-promoting phenotype. Intervening in this crosstalk can improve their capabilities and clinical applications and can make them key components in new therapeutic antileukemic approaches. In this review, we highlight several characteristics of γδ T cells and their interactions in leukemia. Furthermore, we explore strategies for maximizing their antitumor functions, aiming to illustrate the findings destined for a better mobilization of γδ T cells against the tumor. Finally, we outline our perspectives on their therapeutic applicability and indicate outstanding issues for future basic and clinical leukemia research, in the hope of contributing to the advancement of studies on γδ T cells in cancer immunotherapy.

11 citations

Journal ArticleDOI
TL;DR: Christensen et al. as discussed by the authors reported the clinical outcome of 131 hematologic patients with lymphoproliferative diseases, infected with SARS-CoV-2 during the Omicron surge in Israel, between January and March 2022.

9 citations